Sutro Biopharma (STRO) Restructuring Costs (2025)

Sutro Biopharma (STRO) reported Restructuring Costs of $1.6 million for Q4 2025, down 78.39% sequentially from $7.3 million in Q3 2025.

Sutro Biopharma (STRO) Restructuring Costs (2025) Analysis & Trends

Sutro Biopharma (STRO) has 1 years of Restructuring Costs data on file, last reported at $1.6 million in Q4 2025.

For the quarter ending Q4 2025, Restructuring Costs changed N/A year-over-year to $1.6 million; the trailing twelve-month figure through Dec 2025 stood at $26.1 million (changed N/A YoY), and the FY2025 full-year result was $26.1 million, changed N/A from the prior year.
Restructuring Costs fell to $1.6 million in Q4 2025, from $7.3 million in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $13.0 million in Q2 2025 to a low of $1.6 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Sutro Biopharma	192.86 Mn	51.43 Mn	-

Download Data